Related by context. All words. (Click for frequent words.) 77 multicenter prospective 76 multicentre randomized 75 Multicenter Study 75 Prospective Randomized 75 Multicentre 74 Randomised 73 Randomized Study 72 multicenter randomized controlled 71 Prospective Randomized Trial 71 phase IIIb 71 randomized multicenter 71 Pivotal Trial 71 EURIDIS 71 prospective multicenter 71 multicentre 71 Prospective Multicenter 71 Controlled Study 71 Phase III Clinical Trial 71 Study Evaluating 71 Randomized Clinical Trial 70 Controlled Trial 70 multicenter randomized 70 Aneurysm Repair 70 Pooled Analysis 70 Multicenter Phase 70 prospective observational 70 Randomized Evaluation 70 Clinical Evaluation 70 Double Blind Placebo 70 Phase IIIb 70 Clinical Trial Results 70 multicentre randomized double 69 Infarct 69 Acute Ischemic Stroke 69 Acute Myocardial Infarction 69 Randomized Phase 69 multicenter randomized placebo controlled 69 Multicenter Trial 69 Aggressive Reduction 69 Carotid Revascularization Endarterectomy vs. 69 Randomized controlled 69 multicenter phase 69 Patency 69 multicenter randomized clinical 69 ExTRACT TIMI 69 Initiate Phase 69 prospective multicentre 69 Carotid Stenting 69 TAXUS ATLAS 69 randomized multicenter trial 69 Phase 2b Study 69 Placebo Controlled 69 Randomized Double Blind 68 Randomized 68 STENT 68 Oral Fingolimod 68 Randomized Double Blind Placebo 68 Clinical Outcome 68 TMC# C# 68 Multicenter Randomized Double 68 Pivotal Study 68 Ranolazine 68 Intervention Trial 68 II Clinical Trial 68 Randomized Double blind 68 NSABP B 68 PRECISE 68 Phase III Trial 68 prospective randomized multicenter 68 Chronic Heart Failure 68 Pivotal Phase III 68 Randomized Controlled 68 Ischemic Stroke 68 Long Term Efficacy 68 Renal Artery 68 Pivotal Clinical Trial 67 registrational Phase 67 Unstable Angina 67 Thrombolysis 67 multicenter multinational 67 ECASS 67 Left Ventricular Dysfunction 67 nonrandomized 67 prospective randomized controlled 67 Initiated Phase 67 fosbretabulin 67 Observational Study 67 multicenter 67 Randomized Phase II 67 Clinical Efficacy 67 Meets Primary Endpoint 67 Carotid Endarterectomy 67 Platelet Inhibition 67 Intervention Effectiveness 67 Randomized Phase III 67 multicenter placebo controlled 67 Subgroup Analysis 67 Edge STudy 67 Phase III randomized 67 Trial Evaluating 67 HCV SPRINT 67 Intervention Effectiveness CATIE 67 Myocardial Infarction Study 66 Sorafenib HCC Assessment 66 Myocardial Infarction 66 Phase IIIb study 66 Stent Thrombosis 66 Placebo Controlled Trial 66 Risk Stratification 66 multicentre randomized controlled 66 Stent Restenosis 66 Safinamide 66 Sipuleucel T 66 Tyrosine Kinase Inhibitor 66 Severe Sepsis 66 TRANSFORMS 66 multicenter Phase III 66 CLARITY TIMI 66 Randomized Controlled Trials 66 Clinical Antipsychotic Trials 66 Acute Decompensated Heart Failure 66 prospective multicenter randomized 66 prospective nonrandomized 66 multicentre prospective 66 placebo controlled clinical 66 Refractory Angina 66 Prolongs Survival 66 Multicenter Randomized 66 AIR2 Trial 66 COPERNICUS 66 Carotid 66 REALITY Trial 66 Raloxifene Evaluation MORE 66 ENESTnd 66 STRIDE PD 66 Clinical Trial Evaluating 66 Val HeFT 66 phase IIa 66 multicenter Phase II 66 Coronary Revascularization 66 PFO migraine 65 randomized controlled multicenter 65 Placebo controlled 65 Asthma Intervention 65 placebo controlled Phase III 65 ENDEAVOR IV 65 Stenting Trial CREST 65 BRIM2 65 Blind Placebo Controlled Trial 65 Resynchronization 65 Pulmonary Arterial Hypertension 65 ASTEROID 65 Evaluation WISE 65 Left Ventricular 65 Aggressive Drug Evaluation 65 prospective randomized 65 Safety Tolerability 65 Antiplatelet 65 Relapsing Remitting Multiple Sclerosis 65 Angiographic 65 Randomized Placebo Controlled 65 Metastatic Prostate Cancer 65 dose escalation clinical 65 Feasibility Trial 65 Randomized Controlled Trial 65 Trandolapril 65 Patients Undergoing 65 Pivotal Phase 65 Phase III Clinical Trials 65 RECORD1 65 RE LY ® 65 Surgical Treatment 65 Metabolic Efficiency 65 RE LY 65 subanalysis 65 randomized Phase IIb 65 Phase 2b Clinical Trial 65 Tocilizumab 65 PREVAIL 65 Novel Oral 65 Combination REOLYSIN R 65 Venous Thromboembolism 65 BOLDER II 65 Dose Ranging Study 65 BCIRG 65 LUMINATE 65 label multicenter 65 Meta Analysis 64 Long Lesion 64 Multiple Ascending Dose 64 Eluting Stent 64 Hemodialysis Patients 64 LUX Lung 64 PRoFESS 64 Hsp# Inhibitor 64 Systemic Sclerosis 64 multicenter randomized double 64 Relapsed Multiple Myeloma 64 Glucosamine Chondroitin Arthritis 64 Spine Patient Outcomes 64 Adjuvant Therapy 64 BRIM3 64 Intracranial Aneurysms 64 Relapsing Multiple Sclerosis 64 placebo controlled randomized 64 ROCKET AF 64 Pharmacokinetic Study 64 EVEREST II 64 landmark ATHENA 64 Pharmacokinetic 64 Soft Tissue Sarcoma 64 Anticancer Drug 64 JAK Inhibitor 64 Endovascular Valve Edge 64 Randomized Placebo controlled 64 Lung Cancer Trial 64 Successfully Completes Phase 64 Phase IIb Trial 64 Cardiac Resynchronization Therapy 64 EINSTEIN DVT 64 Autologous Stem Cell Transplantation 64 NO# [002] 64 TG MV 64 Radiofrequency Ablation 64 double blinded randomized 64 PERSEUS 64 CALGB # [002] 64 Eluting 64 HCV RESPOND 2 64 RE MODEL 64 Efficacy Trial 64 ADMIRE HF 64 Monotherapy 64 CARE HF 64 Completes Patient Enrollment 64 Phase III placebo controlled 64 EchoCRT 64 Cardiovascular Outcomes 64 Clinical Outcomes Utilizing Revascularization 64 Fondaparinux 64 Patients Treated 64 Stenting Trial 64 Phase Ib clinical 64 Non Alcoholic Steatohepatitis 64 Phase IIb Clinical Trial 64 MIVI III 64 Pegylated Liposomal Doxorubicin 64 Phase III multicenter 64 Prostate AdenoCarcinoma Treatment 64 Aflibercept 64 RADIANT 63 Phase Ib Clinical Trial 63 Benign Prostatic Hyperplasia 63 Aortic Dissection 63 unfractionated heparin UFH 63 Coronary Angiography 63 Pharmacodynamic 63 Cholesterol Levels SPARCL 63 APRICOT 63 Patients Treated With 63 Coronary Artery Bypass Graft 63 REVIVE Diabetes 63 randomized controlled Phase 63 Complicated Skin 63 placebo controlled Phase 63 icatibant 63 Gastric Cancer 63 Phase IIIb clinical 63 Antiviral Therapy 63 Intravascular 63 Drug Eluting Stent System 63 Catheter Ablation 63 AVERROES 63 Digital Mammographic Imaging 63 phase IIa clinical 63 BR.# 63 Randomised Controlled Trial 63 Intracoronary 63 Lupus Nephritis 63 controlled multicenter Phase 63 Overactive Bladder 63 Phase IIB 63 Blind Placebo Controlled 63 Confirms Efficacy 63 Demonstrates Positive 63 ADVANCE PD 63 Patient Outcomes 63 NICE SUGAR 63 CAMMS# 63 Improves Outcomes 63 Cell Lymphoma 63 ABCSG 63 Antiviral Activity 63 Echocardiographic 63 Drug Eluting Stents 63 Dual Antiplatelet Therapy 63 Dupuytren Contracture 63 atypical Hemolytic Uremic Syndrome 63 Multicenter Double 63 CUSTOM II 63 Tanespimycin 63 Neoadjuvant 63 Cardiac Allograft Rejection 63 recurrent malignant glioma 63 Targeted Therapy 63 Patients Enrolled 63 Sirolimus eluting 63 BARI 2D 63 prospectively randomized 63 Placebo Controlled Study 63 randomized multicentre 63 Myocardial Ischemia 63 Percutaneous Tibial Nerve Stimulation 63 CALGB 63 Renal Cell Carcinoma 63 Hormone Refractory Prostate Cancer 63 Acute Coronary Syndromes 63 Intravitreal 63 Optical Coherence Tomography 63 IMPACT DCM 63 Clinical Validation 63 SANTE 63 GOUT 63 multicenter clinical 63 Diabetic Macular Edema 63 observational cohort study 63 NEVO RES 63 CALERIE 63 Combination Treatment 62 Cervical Spine 62 RAVEL 62 Percutaneous Coronary Intervention 62 Prognostic Significance 62 Phase III psoriasis 62 Treatment Naive 62 Screening Trial 62 prospective randomized placebo 62 Venous Thrombosis 62 Adjuvant Treatment 62 Stent Implantation 62 Drug Eluting 62 randomized Phase III 62 Radiation Therapy Oncology 62 multicenter randomized Phase III 62 Heart Failure Patients 62 Heart Failure Trial 62 Bosutinib 62 Randomized Trials 62 PEG IFN 62 Metastatic Renal Cell Carcinoma 62 Completes Enrollment 62 Bare Metal Stent 62 Stenting 62 Dose Escalation 62 Nilotinib 62 VADT 62 Ovarian PLCO Cancer 62 PREVENT IV 62 CLARITY study 62 Shows Efficacy 62 SORT OUT 62 blinded randomized placebo controlled 62 Hematological 62 ADONIS 62 Phase #/#a 62 Revascularization 62 Sirolimus Eluting Stent 62 ONTARGET 62 STARFlex R 62 ARBITER 6 62 Ambulatory Blood Pressure 62 Hepatocellular Carcinoma 62 Severe Asthma 62 Recurrent Glioblastoma 62 MEND CABG 62 Glatiramer Acetate 62 Diabetic Nephropathy 62 RIO Lipids 62 Randomized Comparison 62 Treating Chronic 62 First Patient Enrolled 62 label multicenter Phase 62 ENDEAVOR II 62 Outpatient Setting 62 blind multicenter 62 Angiotensin Converting Enzyme 62 ENDEAVOR 62 Renal Cancer 62 Aortic Valve Replacement 62 Phase 2a Clinical Trial 62 NAVISTAR R 62 Randomized Clinical Trials 62 Nymox NX 62 Study Demonstrates 62 VESTASYNC 62 PHASE III 62 Investigational Treatment 62 Bioequivalence 62 Acute Myocardial 62 Hypoactive Sexual Desire Disorder 62 MADIT II 62 Phase Ib II 62 Adenoma Prevention 62 Preclinical Data 62 masked placebo controlled 62 Remission Maintenance 62 Radical Prostatectomy 62 PRE SURGE 62 See CLINICAL PHARMACOLOGY 62 IIa Clinical Trial 62 Receives Orphan Drug Designation 62 Gynecologic Oncology Group 62 phase IIb clinical 62 Current Controlled Trials 62 Sustained Efficacy 62 dual endothelin receptor antagonist 62 EmbraceAC 62 Granted Orphan Drug 62 ORACLE MS 62 Pharmacodynamics 62 Scandinavian Cardiac Outcomes 62 Treated Patients 62 PRECiSE 62 Shows Promising 62 SPIRIT FIRST 62 Diabetic Foot Ulcer 62 Antitumor Activity 62 Protease Inhibitors 61 Treatment Outcome 61 Histological 61 Aortic Stenosis 61 Malignant Melanoma 61 ID NCT# 61 CAPRIE 61 Phase III Pivotal 61 randomized blinded 61 Patient Enrollment 61 Clostridium difficile Infection 61 Thromboembolism 61 Adalimumab 61 Phase III Pivotal Trial 61 intravitreal insert 61 REFLEX 61 multicentre study 61 Acute Stroke 61 MADIT 61 Antihypertensive 61 CIMZIA TM certolizumab pegol 61 Bucindolol 61 REALISM 61 Well Tolerated 61 substudy 61 Podium Presentation 61 Knee Osteoarthritis 61 Infarction 61 Intravesical 61 Dose Response 61 Cardiovascular Events 61 Contrast Enhanced 61 HYVET 61 Phase 2b Trial 61 IN PATIENTS WITH 61 Temsirolimus 61 Laryngeal Cancer 61 Oral Calcitonin 61 DIRECT Trial 61 Antigen Specific 61 ERATO 61 Phase IIa Clinical Trial 61 Nesiritide 61 Phase IIA 61 Endoluminal 61 Treatment Resistant 61 Prospective Randomized Study 61 Initiates Clinical 61 multicenter study 61 Adjuvant Chemotherapy 61 Orally Active 61 Prostate Lung Colorectal 61 Cardiotoxicity 61 phase Ib 61 TO AVOID PREGNANCY WHILE 61 Arimidex Tamoxifen Alone 61 ENDEAVOR III 61 Denufosol 61 randomized controlled clinical 61 International Verapamil SR 61 Anti Tumor Activity 61 treatment naive genotype 61 multicentric 61 Bipolar Disorders 61 Degarelix 61 POISE 61 Eluting Coronary Stent System 61 randomized crossover 61 BOLDER 61 HALTS 61 Multiethnic Study 61 FREEDOMS 61 Phase Ib IIa 61 EORTC 61 Lipid Lowering Treatment 61 relapsing multiple sclerosis 61 Unfractionated Heparin 61 Postmenopausal Women 61 Oral Insulin Capsule 61 Improves Survival 61 Female Urology 61 trials RCTs 61 Diastolic Heart Failure 61 Advanced Heart Failure 61 Peripheral Arterial 61 ILLUSTRATE 61 landmark ATHENA trial 61 Preclinical Study 61 Intracranial 61 Cardiogenic Shock 61 Prospective Cohort Study 61 PEGylated interferon beta 1a 61 ASSERT 61 metastatic malignant 61 Phase III Psoriasis 61 Endovascular Repair 61 Sapacitabine 61 HepaSphere 61 Clinical Study 61 Desvenlafaxine Succinate 61 Deforolimus 61 Prognostic Value 61 Adjunctive 61 Initiates Phase III 61 Restenosis 61 Zenvia Phase III 61 Pharmacokinetics PK 61 RE LY trial 61 STICH 61 Bone Metastases 61 By JENNIFER LEARN 61 antibody blinatumomab MT#/MEDI-# 61 Investigational Drug 61 Investigational Compound 61 ISAR TEST 61 R lenalidomide 61 Neuroprotective Effects 61 BERKELEY CA UroToday.com 61 controlled multicenter 61 PCI ExTRACT TIMI 61 Paroxysmal Nocturnal Hemoglobinuria PNH 61 Therapeutic Targets 61 PROTEGE 61 number NCT# ClinicalTrials.gov 61 Phase 1b clinical 61 Metastatic Melanoma 61 #:#-# [031] 61 Vertebral Fracture 61 thorough QT 61 Investigational Agent 61 Phase 2b kidney transplant 61 Fungal Infections 61 Sequenced Treatment Alternatives 61 Valve Replacement 61 SORT OUT III 61 Kinase Inhibitor 61 ORENCIA ® 61 HDAC Inhibitor 61 First Patient Dosed 61 RNAi Therapeutic 61 Enzastaurin 61 Advanced Melanoma 61 Endarterectomy 61 Demonstrates Significant 61 Demonstrates Efficacy 61 Statistically Significant 61 Adverse Event 61 Ziprasidone 61 ACTEMRA TM 61 Initiates Enrollment 61 longitudinal cohort study 61 Double Blind Randomized 61 Pharmacologic 61 Sirolimus eluting Coronary Stent 61 J Clin 61 Randomised Study 61 pain palliation 61 GISSI 61 Vascular Disrupting Agent 61 Histologic 61 ENVISION 61 Cardiac Resynchronization 61 Tumor Response 60 Postmenopausal Osteoporosis 60 Nephropathy 60 Solid Tumors 60 Bivalirudin 60 Advanced Renal Cell 60 Scandinavian Simvastatin Survival 60 Novel Inhibitor 60 TRITON TIMI 60 Chronic Hepatitis B 60 Plaque Psoriasis 60 Proves Effective 60 Controlled Clinical Trial 60 Inflammatory Arthritis 60 Multicenter Automatic Defibrillator Implantation 60 Shows Promise Against 60 CCX# B 60 CORD II 60 Systematic Review 60 THAT ARE DIFFICULT TO 60 Chronic Lymphocytic Leukemia 60 Surgical Procedures 60 transcranial Doppler ultrasound 60 Recurrent Breast Cancer 60 Single Dose 60 Previously Treated 60 Kinase Inhibitors 60 Clinical Practice Guideline 60 complement inhibitor eculizumab 60 Ischemic 60 Prospective Randomized Double 60 carotid artery stenting CAS 60 Aortic Valve 60 Initiates Phase II 60 prospective multicenter study 60 treat benign prostatic 60 Dasatinib 60 Cimzia ® certolizumab pegol 60 TAXUS V 60 APEX PD 60 DAPT Study 60 VICTOR E1 60 Clinical Trial 60 ST Segment Elevation 60 Follicular Lymphoma 60 Newly Diagnosed Multiple Myeloma 60 #:#-# [029] 60 Tiotropium 60 Central Retinal Vein 60 Elderly Patients 60 phase IIb study 60 CLL8 60 Postmenopausal Hormone Therapy 60 Metastatic Colorectal Cancer 60 CHAMPION PCI 60 Watchful Waiting 60 Brentuximab Vedotin SGN 60 DA VINCI 60 Systolic Hypertension 60 Topline Results 60 Acute Heart Failure 60 Immunomedics Announces 60 TROPIC 60 Phase III AFFIRM 60 CABG Surgery 60 Phase IIb III 60 relapsing remitting MS RRMS 60 ST Elevation Myocardial 60 Stable Angina 60 Chemoradiation 60 ritonavir boosted 60 Tigecycline 60 Rheumatoid Arthritis Patients 60 Investigator Initiated 60 Partial Onset Seizures 60 Epoetin Alfa 60 Medoxomil 60 sirolimus eluting 60 Mycophenolate Mofetil 60 orally inhaled migraine 60 occlusion CRVO 60 somatostatin analog 60 Chronic Hepatitis C 60 CELLO 60 Neoplasia 60 Lodotra TM 60 Patients Receiving 60 Microalbuminuria 60 Biomarker Study 60 Atopic Dermatitis 60 prucalopride 60 Diamyd Medical Diamyd 60 Neoadjuvant Chemotherapy 60 IIa clinical 60 multicenter randomized Phase 60 NEVO 60 dose escalation Phase 60 Localized Prostate Cancer 60 #:#-# [007] 60 Percutaneous Transluminal Coronary Angioplasty 60 Initiates Clinical Trial 60 Clinical Relevance 60 Confirmatory Phase 60 EXPLORE Xa 60 Endeavor Drug Eluting 60 conducted retrospective cohort 60 Bone Mineral Density 60 Trial ASCOT 60 Efficacy Results 60 Cardiac Rhythm 60 Synta Announces 60 NATRECOR ® 60 Microplasmin 60 Breast Ultrasound 60 MR Angiography 60 Heterozygous Familial Hypercholesterolemia 60 Nicotine Vaccine 60 MIST II 60 Etanercept 60 MERLIN TIMI 60 Implantable Defibrillator 60 ongoing Phase 1b 60 Vertebroplasty 60 Myelodysplastic Syndromes 60 briakinumab 60 ICON7 60 Contrast Agent 60 HuMax EGFr 60 J Am Coll 60 Natalizumab 60 RezularTM 60 Cytotoxicity 60 Pulmonary Artery 60 ACCLAIM 60 ENGAGE AF TIMI 60 PEGINTRON TM 60 Corneal Transplant 60 Xelox 60 Eculizumab 60 Protease Inhibitor 60 Presents Positive 60 DASISION 60 randomized blinded placebo 60 Lung Injury 60 LHRH receptor positive 60 REMINDER ORLive Presents 60 Tolvaptan 60 Pivotal Trials 60 Systemic Juvenile Idiopathic 60 CURRENT OASIS 7 60 UNLOAD 60 RENAL 60 Acute Coronary 60 Female Stress Urinary 60 Medidur TM FA 60 occipital nerve stimulation 60 Coagulation 60 Drug Candidate 60 Carotid Artery Stenting 60 Decompensated Heart Failure 60 CHARISMA trial 60 Antiepileptic Drug 60 Arch Surg 60 ACCOMPLISH 60 Allergic Rhinitis 60 Phase 2a Trial 60 Clinical Trial Data 60 transurethral 60 Elagolix 60 ATTRACT 60 Screening Trial DMIST 60 Balloon Angioplasty 60 Paclitaxel Eluting 60 blinded randomized 60 Cutaneous T 60 randomized placebo controlled 60 NCCTG N# 60 DEFER 60 Neovascular Age Related Macular 60 Differential Diagnosis 60 Preclinical Models 60 XIENCE V PROMUS Stent 60 WallFlex Biliary RX 60 Reduces Mortality 60 riociguat 60 Parathyroid Hormone 60 ROADMAP 60 PARTNER Trial 60 Contrast Agents 60 Depressive Symptoms 60 Overactive Bladder OAB 60 IND Application 60 Renal Transplantation 60 Total Knee Arthroplasty 60 TM Everolimus Eluting 60 AIR CF1 59 Relapsed Refractory 59 Diabetic Neuropathy 59 Initiates Phase 2b 59 Phase 1a clinical 59 Demonstrates Sustained 59 Gastrointestinal Stromal Tumors 59 Molecular Basis 59 Insulin Therapy 59 Potent Inhibitor 59 sorafenib Nexavar 59 Deutsches Herzzentrum 59 ORLive Presents 59 Embolic Protection 59 Hospital Acquired Pneumonia 59 Women Ischemia Syndrome 59 Schizophrenia Treatment 59 double blinded placebo 59 Randomised Trial 59 retrospective cohort 59 Transdermal Patch 59 Ischemic Events 59 #-# Full Text 59 Long Term Outcomes 59 Drug Shows Promise 59 Eur J 59 Enoxaparin 59 Early Relapsing Multiple 59 Zoledronic Acid 59 Valvular 59 Left Atrial 59 Sandostatin R 59 Ovarian Cancer Screening 59 longitudinal observational study 59 Hepatitis C Genotype 59 placebo controlled 59 Pre RELAX AHF 59 NCIC CTG 59 Progenitor Cells 59 TM Drug Eluting 59 PLCO 59 Myocardial Perfusion 59 Juvenile Idiopathic Arthritis 59 phase IIb III 59 Effectively Treats 59 Liver Metastases 59 Atypical Hemolytic Uremic Syndrome 59 FDA APPROVES 59 CABANA 59 Valsartan 59 Commences Phase 59 Peginterferon 59 Pharmaceuticals Initiates 59 Arch Neurol 59 Diabetic Patients 59 randomized clinical 59 Subgroup analysis 59 multicenter Phase 59 HER2 Positive Breast Cancer 59 GEM OS1 59 dyskinesia PD LID 59 Postdoctoral Position 59 PROMUS R 59 Protein Expression 59 Poster Presentations 59 Laparoscopic Surgery 59 blind randomized 59 Myelodysplastic Syndrome MDS 59 Alpha Tocopherol Beta Carotene 59 Uterine Fibroid Embolization 59 RoACTEMRA 59 Invasive Breast Cancer 59 Luteinizing Hormone Releasing Hormone 59 Minimally Invasive Treatment 59 Anthrax Toxin 59 Prostatectomy 59 Conjugate 59 APPRAISE 59 Breast Cancer Recurrence 59 blind randomized placebo 59 Files IND 59 ARBITER 59 J Clin Oncol 59 evaluating tivozanib 59 Virologic 59 Implantable Cardioverter Defibrillator 59 Endovascular Treatment 59 retrospective observational study 59 ABSORB trial 59 CUSTOM III 59 OLYMPIA registry 59 Fabry Disease 59 Breast Carcinoma 59 Study Shows Significant 59 Treatment Experienced 59 Improve Survival 59 MEND CABG II 59 Ranibizumab 59 Daptomycin 59 Amrubicin 59 Drug Eluting Coronary Stent 59 Cypher Sirolimus 59 COSTAR II 59 undergoing Percutaneous Coronary 59 PFO closure 59 Blood Pressure Monitoring 59 SORIN 59 Adenomas 59 randomized #:#:# 59 Ozarelix 59 Survival Benefit 59 Asymptomatic Carotid 59 Rosuvastatin 59 PROTECT AF 59 EuroIntervention 59 multinational multicenter randomized 59 Achieves Primary Endpoint 59 STRATEGY FOR AN OPEN 59 Systemic Lupus Erythematosus 59 Transcatheter 59 epoetin alpha 59 Patient Enrolment 59 Adjunctive Therapy 59 Enzyme Replacement Therapy 59 V Everolimus Eluting Coronary 59 Chronic HCV 59 Bazedoxifene 59 Dalbavancin 59 Septic Shock 59 label dose escalation 59 Polymorphism 59 NCT# ClinicalTrials.gov 59 Pertuzumab 59 Cardiovascular Risk Factors 59 Diabetes Interventions 59 stage IIIB 59 Endometrial Cancer 59 Mechanistic 59 Dose Finding 59 blinded placebo controlled 59 Betaferon R 59 Pharmacokinetic Pharmacodynamic 59 Blood Pressure Lowering 59 AIR CF2 59 Accelerated Partial Breast Irradiation 59 Male Infertility 59 Abstract Accepted 59 nab paclitaxel 59 Critical Limb Ischemia CLI 59 evaluating Vectibix 59 morphometric vertebral fractures 59 Intravenous Equipment 59 relapsed MM 59 toenail onychomycosis 59 Neovascular AMD 59 Beta Blocker 59 Hepatotoxicity 59 receptor tyrosine kinase inhibitor 59 Study Showed 59 Group RTOG 59 TRA 2P 59 Drug Eluting Stent 59 interferon beta 1b 59 biliary tract cancer 59 keloid scarring 59 Therapy Evaluation 59 AVADO 59 Cancer Prevention ATBC 59 blind randomized controlled 59 #F FDG PET CT 59 Artificial Organs 59 Is Well Tolerated 59 Phase III randomized controlled 59 Practice Patterns 59 Late Breaker 59 liposome injection 59 HDL Selective Delipidation 59 Cardiovascular Risk Reduction 59 Prostate Cancer Prevention 59 Anti CD# Antibody 59 Therapeutic Effects 59 Tolerability 59 GELA 59 ZYBRESTAT fosbretabulin 59 Epithelial Cell 59 Lumbar Spine 59 Reduced Incidence 59 Fixed Dose 59 Intracerebral 59 ACRIN 59 REG1 Anticoagulation System 59 Appropriateness Criteria 59 DEFINITIVE AR 59 Hypertensive Patients 59 PERSEUS clinical program 59 Anticancer Activity 59 Coronary CTA 59 Castration Resistant Prostate Cancer 59 Prostate Biopsy 59 Clinical Outcomes 59 induced macular edema 59 oral dual endothelin 59 Suicidality 59 Tesamorelin 59 pharmacokinetic PK study 59 Oral Cladribine 59 J Clin Endocrinol Metab 59 Biological Effects 59 Immune Mediated 59 Systemic Delivery 59 MGd 59 ADAGIO 59 Vascugel 59 comparing XIENCE V 59 Hernia Repair